focus -WSS

focus

author：entertainment 2025-08-23 06:45:17 - browse：24259

Rising drug prices —Medicare coverage from STAT — Medicare on Friday released new details about how its new drug price negotiation program will work, just two months before it’s set to start. APStock

WASHINGTON — Medicare on Friday released new details about how its new drug price negotiation program will work, just two months before it’s set to start.

Medicare released an initial outline of how the program will work in March. Some parts, including the outline of how drugs would be selected for the negotiation process, were immediately final. The agency asked drug companies, patients, and other affected parties to weigh in on other parts about how the process would proceed, what factors would be considered, and how drugmakers would be held accountable.

Newsletters

Sign up for D.C. Diagnosis

An insider's guide to the politics and policies of health care

Please enter a valid email address. Privacy Policy

The negotiation process was created last August in Democrats’ drug pricing reform law, and Medicare is supposed to select the first 10 drugs that will be subject to negotiation by Sept. 1.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies
Next article： Can sheer will power keep patients alive in their dying hours?

focus

WSS

STAT Summit: Meghan O’Rourke on making chronic illness visible

Why health records don't always know when patients are dead

STAT Summit: How researchers deal with rejection

STAT Health News: Apple Watch import ban, Pfizer fumbles, etc

Is there really a nursing shortage in the U.S.?

Study on Amgen’s bispecific immunotherapy produces positive data

entertainment

focus

Sign up for D.C. Diagnosis

leisure time

FDA approval of Sarepta Duchenne genetic therapy gives me hope

UnitedHealth, Optum discontinue NaviHealth name

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Grail spinoff by Illumina should end disastrous merger attempt

Malaria cases in Florida and Texas: Here’s what you need to know

STAT Summit: How researchers deal with rejection

23andMe had bad news about my health. I wish a person had delivered it

HCA sued by state AG for quality issues at Mission Health

Wildfire smoke exposes gaps in outdoor worker protections

CRISPR gene editing developments we’re watching in 2024

focus

Editas, Vertex strike deal on CRISPR

Why a market frenzy over new weight loss drugs defies logic

Christmas in the PICU brings some surprising joy

FDA clears Verve to begin U.S. study of gene

Keeping primary care docs in field isn't impossible, says AAFP CEO

Roche drug slashes death risk in early

focus

focus

hotspot

hotspot